{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:12:07Z","timestamp":1762283527062,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.yrtph.2014.07.012","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T16:06:04Z","timestamp":1405526764000},"page":"242-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment"],"prefix":"10.1016","volume":"70","author":[{"given":"William","family":"Jo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nejishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakazu","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Minowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Calvarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Senda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishnan","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yrtph.2014.07.012_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis. Treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"issue":"9","key":"10.1016\/j.yrtph.2014.07.012_b0010","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","article-title":"Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions","volume":"133","author":"Elewski","year":"1997","journal-title":"Arch. Dermatol."},{"issue":"6 Pt 2","key":"10.1016\/j.yrtph.2014.07.012_b0015","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0190-9622(99)70397-X","article-title":"Onychomycosis: therapeutic update","volume":"40","author":"Scher","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl 64","key":"10.1016\/j.yrtph.2014.07.012_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.149.s65.4.x","article-title":"Epidemiology, clinical presentation and diagnosis of onychomycosis","volume":"149","author":"Faergemann","year":"2003","journal-title":"Brit. J. Dermatol."},{"key":"10.1016\/j.yrtph.2014.07.012_b0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1529-8019.2007.00109.x","article-title":"Toenail onychomycosis: current and future treatment options","volume":"20","author":"Finch","year":"2007","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.yrtph.2014.07.012_b0030","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","article-title":"Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis","volume":"57","author":"Jo Siu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.yrtph.2014.07.012_b0035","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of action of efinaconazole, a novel triazole antifungal agent","volume":"57","author":"Tatsumi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.yrtph.2014.07.012_b0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.yrtph.2014.07.012_b0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0192623312448935","article-title":"Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes\u2013conclusions from the 3rd International ESTP Expert Workshop","volume":"40","author":"Hall","year":"2012","journal-title":"Toxicol. Pathol."},{"issue":"9","key":"10.1016\/j.yrtph.2014.07.012_b0050","first-page":"1010","article-title":"Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis: low systemic exposure suggests remote drug-drug interaction potential","volume":"12","author":"Jarratt","year":"2013","journal-title":"J. Drugs Dermatol."},{"issue":"3","key":"10.1016\/j.yrtph.2014.07.012_b0055","first-page":"20","article-title":"Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential","volume":"6","author":"Del Rosso","year":"2013","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"6","key":"10.1016\/j.yrtph.2014.07.012_b0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10915810600961531","article-title":"Nonclinical vehicle use in studies by multiple routes in multiple species","volume":"25","author":"Gad","year":"2006","journal-title":"Int. J. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2014.07.012_b0065","first-page":"170","article-title":"Hepatotoxicity of antifungal agents","volume":"6","author":"Song","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.yrtph.2014.07.012_b0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1191\/0960327104ht479oa","article-title":"Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study","volume":"23","author":"Somchit","year":"2004","journal-title":"Hum. Exp. Toxicol."},{"issue":"1","key":"10.1016\/j.yrtph.2014.07.012_b0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mrgentox.2008.09.011","article-title":"Evaluation of the genotoxicity of the imidazole antifungal climbazole: comparison to published results for other azole compounds","volume":"672","author":"Perez-Rivera","year":"2009","journal-title":"Mutat. Res."},{"issue":"6","key":"10.1016\/j.yrtph.2014.07.012_b0080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/019262339302100603","article-title":"Incidence of spontaneous neoplastic and nonneoplastic lesions in Charles River CD-1 mice varies with breeding origin","volume":"21","author":"Engelhardt","year":"1993","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.yrtph.2014.07.012_b0085","first-page":"95","article-title":"Progressive necrosing dermatitis of the pinna in outbred mice: an institutional study","volume":"48","author":"Slattum","year":"1998","journal-title":"Lab. Anim. Sci."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230014001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230014001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:07:21Z","timestamp":1762283241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230014001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0273230014001676"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2014.07.012","relation":{},"ISSN":["0273-2300"],"issn-type":[{"type":"print","value":"0273-2300"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2014.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}